The effects of low-dose Nepsilon-(carboxymethyl)lysine (CML) and Nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell function

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Zhu, Jinzhou ^a   Yang, Ke ^b   Jing, Yajun ^b   Du, Run ^a   Zhu, Zhenbin ^a   Lu, Lin ^a,b   Zhang, Ruiyan ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Endothelial progenitor cells; Mitogen activated protein kinases; N lunate (carboxyethyl)lysine; N lunate (carboxymethyl)lysine; Uremic toxins

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; DICARBOXYLIC AMINO ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N EPSILON (CARBOXYETHYL)LYSINE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PATHOGENESIS; TOXICITY TESTING; TOXIN ANALYSIS; UREMIA; URINARY EXCRETION;

APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; RECEPTORS, IMMUNOLOGIC; STEM CELLS; TIME FACTORS; TOXINS, BIOLOGICAL; UREMIA;

EID: 84867522530     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-90     Document Type: Article

References (55)

1. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999, 56:2214-2219. 10.1046/j.1523-1755.1999.00773.x, 10594797.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305. 10.1056/NEJMoa041031, 15385656.
3. Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-George F, Jourde-Chiche N, Argiles A, Burtey S. Does uremia cause vascular dysfunction?. Kidney Blood Press Res 2011, 34:284-290. 10.1159/000327131, 21691132.
4. Goligorsky MS, Yasuda K, Ratliff B. Dysfunctional endothelial progenitor cells in chronic kidney disease. J Am Soc Nephrol 2010, 21:911-919. 10.1681/ASN.2009111119, 20395371.
5. Mohandas R, Segal MS. Endothelial progenitor cells and endothelial vesicles - what is the significance for patients with chronic kidney disease?. Blood Purif 2010, 29:158-162. 10.1159/000245643, 2914407, 20093822.
6. Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004, 24:1246-1252. 10.1161/01.ATV.0000133488.56221.4a, 15155385.
7. Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Amemiya M, Takano R, Kusano E, Shimada K, Ikeda U. Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin 2003, 19:627-633. 10.1185/030079903125002379, 14606986.
8. Westerweel PE, Hoefer IE, Blankestijn PJ, de Bree P, Groeneveld D, van Oostrom O, Braam B, Koomans HA, Verhaar MC. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol 2007, 292:F1132-F1140.
9. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005, 111:363-368. 10.1161/01.CIR.0000153339.27064.14, 15668353.
10. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999, 10:1815-1823.
11. Vanholder R, De Smet R, Lameire N. Protein-bound uremic solutes: the forgotten toxins. Kidney Int Suppl 2001, 78:S266-S270.
12. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P. Protein-bound toxins-update 2009. Semin Dial 2009, 22:334-339. 10.1111/j.1525-139X.2009.00576.x, 19708977.
13. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P. Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011, 24:327-337. 10.1111/j.1525-139X.2011.00925.x, 21682773.
14. Chen JZ, Zhu JH, Wang XX, Xie XD, Sun J, Shang YP, Guo XG, Dai HM, Hu SJ. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 2004, 36:233-239. 10.1016/j.yjmcc.2003.10.005, 14871551.
15. Jourde-Chiche N, Dou L, Sabatier F, Calaf R, Cerini C, Robert S, Camoin-Jau L, Charpiot P, Argiles A, Dignat-George F, Brunet P. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009, 7:1576-1584. 10.1111/j.1538-7836.2009.03540.x, 19583820.
16. Piroddi M, Depunzio I, Calabrese V, Mancuso C, Aisa CM, Binaglia L, Minelli A, Butterfield AD, Galli F. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids 2007, 32:573-592. 10.1007/s00726-006-0433-8, 17356806.
17. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003, 63:1934-1943. 10.1046/j.1523-1755.2003.00924.x, 12675874.
18. Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009, 104:42-49. 10.1007/s00395-008-0738-8, 18622638.
19. Chen Q, Dong L, Wang L, Kang L, Xu B. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem Biophys Res Commun 2009, 381:192-197. 10.1016/j.bbrc.2009.02.040, 19232321.
20. Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M. Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol 2012, 11:46. 10.1186/1475-2840-11-46, 3403843, 22545734.
21. Palombo C, Kozakova M, Morizzo C, Gnesi L, Barsotti MC, Spontoni P, Massart F, Salvi P, Balbarini A, Saggese G, Di Stefano R, Federico G. Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes. Cardiovasc Diabetol 2011, 10:88. 10.1186/1475-2840-10-88, 3198903, 21981808.
22. Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, Kimura S. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 2007, 377:213-220. 10.1016/j.cca.2006.09.028, 17118352.
23. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005, 16:1471-1485. 10.1681/ASN.2004080635, 15800128.
24. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A. Normal and Pathologic Concentrations of Uremic Toxins. J Am Soc Nephrol 2012, 23:1258-1270. 10.1681/ASN.2011121175, 22626821.
25. Wagner Z, Molnar M, Molnar GA, Tamasko M, Laczy B, Wagner L, Csiky B, Heidland A, Nagy J, Wittmann I. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 2006, 47:294-300. 10.1053/j.ajkd.2005.10.010, 16431258.
26. Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 2009, 22:74-79. 10.1038/ajh.2008.320, 2637811, 19023277.
27. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, Chen D. Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012, 221:387-396. 10.1016/j.atherosclerosis.2012.01.019, 22305260.
28. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, Danze PM, Dequiedt P. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002, 61:148-156. 10.1046/j.1523-1755.2002.00115.x, 11786095.
29. Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R. In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 2004, 66:1873-1880. 10.1111/j.1523-1755.2004.00961.x, 15496158.
30. Ying Y, Yang K, Liu Y, Chen QJ, Shen WF, Lu L, Zhang RY. A uremic solute, P-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway. Circ J 2011, 75:2252-2259. 10.1253/circj.CJ-11-0046, 21747198.
31. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103:921-926.
32. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010, 106:842-853. 10.1161/CIRCRESAHA.109.212217, 2862596, 20299674.
33. Thornalley PJ, Rabbani N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009, 22:400-404. 10.1111/j.1525-139X.2009.00589.x, 19708990.
34. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997, 51:1170-1181. 10.1038/ki.1997.160, 9083283.
35. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003, 375:581-592. 10.1042/BJ20030763, 1223712, 12885296.
36. Sengoelge G, Fodinger M, Skoupy S, Ferrara I, Zangerle C, Rogy M, Horl WH, Sunder-Plassmann G, Menzel J. Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Kidney Int 1998, 54:1637-1651. 10.1046/j.1523-1755.1998.00157.x, 9844140.
37. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996, 97:238-243. 10.1172/JCI118397, 507085, 8550841.
38. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280:E685-E694.
39. Yang K, Wang XQ, He YS, Lu L, Chen QJ, Liu J, Shen WF. Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol 2010, 9:66. 10.1186/1475-2840-9-66, 2987998, 20969783.
40. Glorieux G, Vanholder R, Lameire N. Advanced glycation and the immune system: stimulation, inhibition or both?. Eur J Clin Invest 2001, 31:1015-1018. 10.1046/j.1365-2362.2001.00910.x, 11903485.
41. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Horl WH. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007, 22:3381-3390. 10.1093/ndt/gfm210, 17724037.
42. Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 1999, 42:603-607. 10.1007/s001250051201, 10333054.
43. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912. 10.1126/science.1072682, 12471242.
44. Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 2005, 45:321-325. 10.1161/01.HYP.0000154789.28695.ea, 15655116.
45. Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res 2007, 31:439-444. 10.1016/j.leukres.2006.10.014, 17113640.
46. Cook SJ, McCormick F. Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells. Biochem J 1996, 320(Pt 1):237-245. 1217923, 8947493.
47. Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997, 14:1635-1642. 10.1038/sj.onc.1201000, 9135064.
48. Weber JD, Raben DM, Phillips PJ, Baldassare JJ. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 1997, 326(Pt 1):61-68. 1218637, 9337851.
49. Jones SM, Kazlauskas A. Growth factor-dependent signaling and cell cycle progression. FEBS Lett 2001, 490:110-116. 10.1016/S0014-5793(01)02113-5, 11223025.
50. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002, 4:556-564.
51. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 2001, 3:165-172. 10.1038/35055073, 11175749.
52. Buetler TM, Leclerc E, Baumeyer A, Latado H, Newell J, Adolfsson O, Parisod V, Richoz J, Maurer S, Foata F, Piguet D, Junod S, Heizmann CW, Delatour T. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 2008, 52:370-378. 10.1002/mnfr.200700101, 18320574.
53. Valencia JV, Weldon SC, Quinn D, Kiers GH, DeGroot J, TeKoppele JM, Hughes TE. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 2004, 324:68-78. 10.1016/j.ab.2003.09.013, 14654047.
54. Nagai R, Mera K, Nakajou K, Fujiwara Y, Iwao Y, Imai H, Murata T, Otagiri M. The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs. Biochim Biophys Acta 2007, 1772:1192-1198. 10.1016/j.bbadis.2007.09.001, 18053692.
55. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML. Uremic toxicity: present state of the art. Int J Artif Organs 2001, 24:695-725.